Aqueous pharmaceutical composition containing serum albumin and growth hormone fusion protein

Abstract

To provide aqueous pharmaceutical compositions containing a fused protein of a serum albumin and growth hormone.SOLUTION: Disclosed is an aqueous pharmaceutical composition comprising a fusion protein between human serum albumin and a human growth hormone as an effective ingredient, where the composition comprises the fused protein at a concentration of 10-100 mg / mL, sucrose at a concentration of 10-150 mg / mL, a nonionic surfactant at a concentration of 0.15-10 mg / mL, an antiseptic agent at a concentration of 0.5-12 mg / mL and a buffer at a concentration of 1-30 mM where pH is 5.0-8.0.SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] The present invention relates to an aqueous pharmaceutical composition that is storage stable in a solution state, for example of a medicine containing a fusion protein of serum albumin and growth hormone as an active ingredient, and more specifically, to an aqueous pharmaceutical composition that further contains sucrose and a nonionic surfactant as stabilizers. [Background technology]

[0002] Human growth hormone (hGH) is a protein secreted from the anterior pituitary gland under the control of the hypothalamus. hGH promotes growth by promoting cartilage formation and protein assimilation, and also improves body composition and lipid metabolism. Children with low levels of hGH secretion develop growth hormone deficiency dwarfism, which results in shorter stature than normal children.

[0003] Preparations containing hGH with a molecular weight of about 22KD as an active ingredient, which is produced as a recombinant protein using Escherichia coli with an hGH gene introduced therein (hGH preparations), are widely used clinically as a treatment for short stature due to growth hormone deficiency, short stature in Turner syndrome, short stature due to SGA (Small-for-Gestational Age), short stature in Noonan syndrome, short stature due to chronic renal failure, short stature in Prader-Willi syndrome, and short stature in chondrodystrophy. hGH preparations are particularly effective in cases where epiphyseal closure is not present in these diseases. hGH preparations are administered subcutaneously or intramuscularly and circulate in the blood, promoting the growth of patients through their growth-promoting activity. hGH preparations are also widely used clinically as a treatment for adult growth hormone deficiency. Patients with adult growth hormone deficiency have various abnormalities, such as lipid metabolism disorders, but administration of hGH preparations normalizes the lipid metabolism of patients, improving their QOL. An example of an hGH preparation for short stature due to growth hormone deficiency, adult growth hormone deficiency, etc. is Growject (registered trademark).

[0004] The half-life of hGH in plasma is less than 20 minutes, and hGH administered to a patient is rapidly eliminated from the blood. For this reason, in order for hGH to have a substantial effect on a patient, it is necessary to administer hGH intramuscularly three times a week or subcutaneously daily. Such frequent administration places a burden on patients. Therefore, if it is possible to increase the stability of hGH in plasma and extend its half-life, thereby reducing the number of times hGH is administered to patients, this would be preferable, as it would reduce the burden on patients.

[0005] Human serum albumin (HSA) is a protein whose mature form consists of 585 amino acids. HSA is the most abundant component of plasma proteins and has a long half-life in plasma of 14 to 20 days. HSA contributes to regulating the osmotic pressure of plasma, and also has the function of binding to and transporting cations, fatty acids, hormones, bilirubin, and other endogenous substances in the blood, as well as exogenous substances such as drugs. In general, substances bound to HSA are less likely to be taken up by organs and are able to circulate in the blood for a longer period of time.

[0006] It is known that there are several natural variants of human serum albumin (HSA). Human serum albumin Redhill is one of them (Non-Patent Documents 1, 2). Human serum albumin Redhill is different from the amino acid sequence of the above-mentioned normal human serum albumin, which consists of 585 amino acids, in that the 320th amino acid residue from the N-terminus is threonine instead of alanine, and an arginine residue is added to the N-terminus, and consists of 586 amino acids. Due to the above-mentioned change of alanine to threonine, a sequence represented by Asn-Tyr-Thr is generated in the amino acid sequence of albumin Redhill, and the Asn (asparagine) residue in this sequence is N-linked glycosidic. For this reason, albumin Redhill is observed to have a molecular weight about 2.5 kDa larger than that of the above-mentioned normal human serum albumin.

[0007] Methods have been reported for increasing the stability of hGH in plasma by binding hGH to HSA (Patent Documents 1 to 8). A protein in which hGH is bound to HSA is produced as a recombinant protein in a medium or within a cell by preparing a transformed cell into which an expression vector has been introduced that incorporates DNA in which a gene encoding hGH and a gene encoding HSA are bound in frame, and culturing the cell. [Prior art documents] [Patent documents]

[0008] [Patent Document 1] WO2017 / 154869 [Patent Document 2] WO2017 / 159540 [Patent Document 3] Special Publication No. 2003-530838 [Patent Document 4] Special Publication No. 2005-514060 [Patent Document 5] Special Publication No. 2000-502901 [Patent Document 6] Special Publication No. 2008-518615 [Patent Document 7] Special Publication No. 2013-501036 [Patent Document 8] Special Publication No. 2013-518038 Summary of the Invention [Problem to be solved by the invention]

[0009] Under the above circumstances, one object of the present invention is to provide an aqueous pharmaceutical composition containing a fusion protein of human albumin and human growth hormone as an active ingredient, which is stable enough to be distributed on the market. [Means for solving the problem]

[0010] As a result of extensive investigations in research aimed at the above-mentioned object, the present inventors discovered that a compound (human serum albumin variant-hGH fusion protein) obtained by binding a variant (human serum albumin variant) consisting of an amino acid sequence in which, compared with normal human serum albumin consisting of 585 amino acids, the 320th amino acid residue from the N-terminus is replaced with threonine is stable in an aqueous pharmaceutical composition containing sucrose and a nonionic surfactant, and thus completed the present invention. That is, the present invention includes the following. 1. An aqueous pharmaceutical composition comprising a fusion protein of human serum albumin and human growth hormone as an active ingredient, wherein the concentration of the fusion protein is 10-100 mg / mL, the concentration of sucrose is 10-150 mg / mL, the concentration of the nonionic surfactant is 0.15-10 mg / mL, the concentration of the preservative is 0.5-12 mg / mL, the concentration of the buffer agent is 1-30 mM, and the pH is 5.0-8.0. 2. The aqueous pharmaceutical composition according to 1 above, wherein the concentration of the fusion protein is 15 to 70 mg / mL. 3. The aqueous pharmaceutical composition according to 1 or 2 above, wherein the concentration of the sucrose is 50 to 100 mg / mL. 4. The aqueous pharmaceutical composition according to any one of 1 to 3 above, wherein the concentration of the nonionic surfactant is 1.5 to 4.5 mg / mL. 5. The aqueous pharmaceutical composition according to any one of 1 to 4 above, wherein the nonionic surfactant is polysorbate or poloxamer. 6. The aqueous pharmaceutical composition according to any one of 1 to 4 above, wherein the nonionic surfactant is selected from the group consisting of polysorbate 20, polysorbate 80 and polyoxyethylene (160) polyoxypropylene (30) glycol. 7. The aqueous pharmaceutical composition according to any one of 1 to 6 above, wherein the preservative is phenol. 8. The aqueous pharmaceutical composition according to the above 7, wherein the concentration of the phenol is 3 to 9 mg / mL. 9. The aqueous pharmaceutical composition according to any one of 1 to 8 above, wherein the buffer is a phosphate buffer. 10. The aqueous pharmaceutical composition according to 9 above, wherein the concentration of the phosphate buffer is 2 to 20 mM. 11. The aqueous pharmaceutical composition according to any one of 1 to 10 above, wherein the pH is 6.0 to 7.8. 12. The aqueous pharmaceutical composition according to any one of 1 to 10 above, wherein the pH is 6.5 to 7.6. 13. The aqueous pharmaceutical composition according to claim 1, wherein the concentration of the fusion protein is 10 to 100 mg / mL, the concentration of the sucrose is 75 mg / mL, the nonionic surfactant is polyoxyethylene (160) polyoxypropylene (30) glycol and the concentration of the polyoxyethylene (160) polyoxypropylene (30) glycol is 3 mg / mL, the preservative is phenol and the concentration of the phenol is 6 mg / mL, the buffer is a phosphate buffer and the concentration of the phosphate buffer is 10 mM, and the pH is 7.0 to 7.4. 14. The aqueous pharmaceutical composition according to claim 1, wherein the concentration of the fusion protein is 15 to 70 mg / mL, the concentration of the sucrose is 75 mg / mL, the nonionic surfactant is polyoxyethylene (160) polyoxypropylene (30) glycol and the concentration of the polyoxyethylene (160) polyoxypropylene (30) glycol is 3 mg / mL, the preservative is phenol and the concentration of the phenol is 6 mg / mL, the buffer is a phosphate buffer and the concentration of the phosphate buffer is 10 mM, and the pH is 7.0 to 7.4. 15. The aqueous pharmaceutical composition according to claim 1, wherein the fusion protein has a concentration of 50 mg / mL, the sucrose has a concentration of 75 mg / mL, the nonionic surfactant is polyoxyethylene (160) polyoxypropylene (30) glycol and the polyoxyethylene (160) polyoxypropylene (30) glycol has a concentration of 3 mg / mL, the preservative is phenol and the phenol has a concentration of 6 mg / mL, the buffer is a phosphate buffer and the phosphate buffer has a concentration of 10 mM, and the pH is 7.0 to 7.4. 16. The liquid pharmaceutical composition according to any one of 1 to 15 above, wherein the amino acid sequence of the fusion protein has an identity of 85% or more with the amino acid sequence shown in SEQ ID NO:11. 17. The liquid pharmaceutical composition according to any one of 1 to 15 above, wherein the amino acid sequence of the fusion protein has 90% or more identity with the amino acid sequence shown in SEQ ID NO:11. 18. The liquid pharmaceutical composition according to any one of 1 to 15 above, wherein the amino acid sequence of the fusion protein has 95% or more identity with the amino acid sequence shown in SEQ ID NO:11. 19. The liquid pharmaceutical composition according to any one of 1 to 15 above, wherein the amino acid sequence of the fusion protein has the amino acid sequence shown in SEQ ID NO:11. Effect of the Invention

[0011] According to the present invention, for example, a pharmaceutical containing a protein formed by binding human albumin and human growth hormone as an active ingredient can be made into a stable aqueous pharmaceutical composition to the extent that it can be distributed on the market. [Brief description of the drawings]

[0012] [Figure 1] Fig. 1 shows the results of measuring the static light scattering intensity of the example. The vertical axis shows the static light scattering intensity (arbitrary units) at 473 nm, and the horizontal axis shows the temperature. In the figure, (a), (b), and (c) are the measurement results for Formulations 2-1, 2-2, and 2-3, respectively. [Diagram 2] Figure 2(a) shows the SE-HPLC chart of Formulation 5-1 in Example 10 immediately after preparation. The vertical axis shows absorbance (arbitrary units) at 215 nm, and the horizontal axis shows retention time (minutes). Figure 2(b) is a diagram enlarged in the vertical direction from Figure 2(a). In the figure, peak 1 corresponds to the monomer of 22KhGH-mHSA, peak 2 to its polymer, peak 3 to its low molecular weight form, and peak 4 to phenol. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] In the present specification, when simply referring to "human serum albumin" or "HSA", in addition to the normal wild-type human serum albumin consisting of 585 amino acid residues as shown in SEQ ID NO: 1, it also includes, without any particular distinction, a mutant of HSA in which one or more amino acid residues have been substituted, deleted, and / or added (as used herein, "addition" of an amino acid residue means adding a residue to the end or inside of the sequence) to the amino acid sequence as shown in SEQ ID NO: 1, so long as it has the functions of normal wild-type human serum albumin, such as the function of binding and transporting endogenous substances in blood and exogenous substances such as drugs. When an amino acid residue is substituted with another amino acid residue, the number of amino acid residues to be substituted is preferably 1 to 10, more preferably 1 to 5, and even more preferably 1 to 3. When an amino acid residue is deleted, the number of amino acid residues to be deleted is preferably 1 to 10, more preferably 1 to 5, and even more preferably 1 to 3. For example, human serum albumin also includes a mutant consisting of 584 amino acid residues in which amino acid residues at the N-terminus or C-terminus of the amino acid sequence shown in SEQ ID NO: 1 have been deleted. Substitution and deletion of these amino acid residues may be combined. Furthermore, one or more amino acid residues may be added to the amino acid sequence of normal wild-type HSA or its mutant, or to the N-terminus or C-terminus of the amino acid sequence. The number of amino acid residues added in this case is preferably 1 to 10, more preferably 1 to 5, and even more preferably 1 to 3.

[0014] Of these three types of mutations, amino acid substitution, deletion, and addition, a mutant of HSA into which at least two types of mutations have been introduced in combination is preferably one having an amino acid sequence in which 0 to 10 amino acid residues have been deleted, 0 to 10 amino acid residues have been substituted with other amino acid residues, and 0 to 10 amino acid residues have been added to the amino acid sequence shown in SEQ ID NO: 1. More preferably, the number of amino acid residues deleted, substituted, and / or added to the amino acid sequence shown in SEQ ID NO: 1 is preferably 5 or less, and more preferably 3 or less.

[0015] In the present invention, the term "human serum albumin Redhill" (HSA-Redhill) refers to a variant of human serum albumin consisting of 586 amino acid residues as shown in SEQ ID NO: 2. Human serum albumin Redhill corresponds to a variant of wild-type human serum albumin consisting of 585 amino acids as shown in SEQ ID NO: 1, in which the 320th amino acid residue from the N-terminus is threonine instead of alanine, and an arginine residue is added to the N-terminus. Due to this substitution of alanine with threonine, a sequence portion represented by Asn-Tyr-Thr is generated in the amino acid sequence of albumin Redhill, and the Asn (asparagine) residue in this sequence portion is N-linked glycosidic. For this reason, albumin Redhill is observed to have a molecular weight about 2.5 kDa larger than that of normal wild-type albumin (SEQ ID NO: 1).

[0016] In the present invention, the term "human serum albumin variant" (HSA variant) refers to the above-mentioned variant of normal wild-type HSA (SEQ ID NO: 1), except for the variant (HSA-Redhill) shown in SEQ ID NO: 2. Preferred HSA variants in the present invention include those shown in SEQ ID NO: 3, in which the alanine at position 320 from the N-terminus of the amino acid sequence of wild-type HSA is replaced with threonine, as well as those having an amino acid sequence in which one or more amino acid residues are replaced with, deleted from, or added to the amino acid sequence shown in SEQ ID NO: 3, with the proviso that the asparagine residue at position 318 from the N-terminus and the threonine residue at position 320 from the N-terminus of the amino acid sequence shown in SEQ ID NO: 3 are preserved in a state in which these two residues are linked by a peptide bond via a single amino acid residue (X) other than proline between these two residues, so long as they have the functions of normal wild-type human serum albumin, such as the function of binding and transporting endogenous substances in blood and exogenous substances such as drugs. When amino acid residues in the amino acid sequence are replaced with other amino acid residues, the number of amino acid residues to be replaced is preferably 1 to 10, more preferably 1 to 5, and even more preferably 1 to 3. When amino acid residues are deleted, the number of amino acid residues to be deleted is preferably 1 to 10, more preferably 1 to 5, and even more preferably 1 to 3. For example, it may be a mutant consisting of 584 amino acid residues in which amino acid residues at the N-terminus or C-terminus of the amino acid sequence shown in SEQ ID NO: 3 are deleted. It may also be a combination of the substitution and deletion of these amino acid residues. Furthermore, it may be a mutant in which one or more amino acid residues are added in the amino acid sequence of the mutant or on the N-terminus or C-terminus side of the amino acid sequence. That is, it may be a mutant in which at least two types of mutations out of three types of mutations, namely, amino acid substitution, deletion, and addition, are introduced into the amino acid sequence shown in SEQ ID NO: 3 in combination, and it may be a mutant in which 0 to 10 amino acid residues are deleted, 0 to 10 amino acid residues are replaced with other amino acid residues, and 0 to 10 amino acid residues are added.However, the 318th to 320th amino acid residues from the N-terminus of the amino acid sequence shown in SEQ ID NO:3 must be asparagine-X-threonine (where "X" is an amino acid residue other than proline), and are preferably asparagine-tyrosine-threonine. Human serum albumin mutants are included in human serum albumin so long as they retain the function of human serum albumin. The amino acid sequence of the human serum albumin mutant here has preferably 85% or more identity, more preferably 90% or more identity, and even more preferably 95% or more identity with the amino acid sequence of normal wild-type HSA shown in SEQ ID NO:1.

[0017] In the present invention, the position and type (deletion, substitution, addition) of each mutation in various HSA mutants compared to normal wild-type HSA can be easily confirmed by aligning the amino acid sequences of both HSAs. In the present invention, the identity between the amino acid sequence of wild-type HSA and the amino acid sequence of HSA with mutations can be easily calculated using a well-known homology calculation algorithm. For example, such algorithms include BLAST (Altschul SF. J Mol. Biol. 215. 403-10, (1990)), Pearson and Lipman's similarity search method (Proc. Natl. Acad. Sci. USA. 85. 2444 (1988)), Smith and Waterman's local homology algorithm (Adv. Appl. Math. 2. 482-9 (1981)), etc.

[0018] Substitutions of amino acids in the above amino acid sequence of HSA with other amino acids occur within amino acid families that are related, for example, by their side chains and chemical properties. Substitutions within such amino acid families are not expected to significantly alter the function of HSA (i.e., are conservative amino acid substitutions). Examples of such amino acid families include: (1) The acidic amino acids aspartic acid and glutamic acid, (2) The basic amino acids histidine, lysine, and arginine (3) Aromatic amino acids such as phenylalanine, tyrosine, tryptophan, (4) Serine and threonine, which are amino acids that have hydroxyl groups (hydroxyamino acids), (5) The hydrophobic amino acids methionine, alanine, valine, leucine, and isoleucine, (6) The neutral hydrophilic amino acids cysteine, serine, threonine, asparagine, and glutamine, (7) Glycine and proline, which are amino acids that affect the orientation of peptide chains, (8) Asparagine and glutamine, which are amide amino acids (polar amino acids), (9) The aliphatic amino acids alanine, leucine, isoleucine, and valine, (10) The amino acids with small side chains, alanine, glycine, serine, and threonine, (11) Alanine and glycine, amino acids with particularly small side chains.

[0019] In the Examples described below, the human serum albumin mutant (a typical example of an HSA mutant) in the protein in which human growth hormone and a human serum albumin mutant are bound differs from the amino acid sequence of wild-type human serum albumin consisting of 585 amino acids (SEQ ID NO: 1) only in that the 320th amino acid residue from the N-terminus is threonine rather than alanine (SEQ ID NO: 3). Due to this difference, in the amino acid sequence of the HSA mutant (referred to as "HSA(A320T)"), a sequence portion represented by Asn-Tyr-Thr occurs, and in this sequence portion, the Asn (asparagine) residue can be N-linked glycosidized.

[0020] In this specification, "a fusion protein of human serum albumin and human growth hormone" or "human serum albumin-hGH fusion protein (HSA-hGH fusion protein)" refers to a protein in which HSA and growth hormone are bound. Here, "binding" these proteins includes, for example, linking them by peptide bonds, but is not limited to this. Furthermore, "binding" these proteins includes not only directly linking the N-terminus of one protein to the C-terminus of the other protein by peptide bonds, but also indirectly binding both proteins via a linker. In particular, when the human serum albumin is a human serum albumin mutant, it is called "a fusion protein of human serum albumin mutant and human growth hormone" or "human serum albumin mutant-hGH fusion protein (HSA mutant-hGH fusion protein)". In other words, the human serum albumin mutant-hGH fusion protein is included in the human serum albumin-hGH fusion protein. "A fusion protein of human serum albumin and human growth hormone" can also be called HSA-linked hGH.

[0021] Here, the "linker" is a structural portion between the two polypeptides and covalently binds them, and is not derived from either the end of HSA (including HSA mutants) or its binding partner growth hormone. The linker can be a single amino acid residue or a peptide chain portion (peptide linker) consisting of two or more amino acid residues that is peptide-bonded to both polypeptides, and linkers consisting of one or more amino acid residues are collectively referred to as "peptide linkers" in this specification. In addition, in this specification, when it is said that HSA and growth hormone are bonded "through a peptide bond," it includes the case where the two are bonded directly through a peptide bond and the case where the two are bonded through a bond with a peptide linker. In this specification, when HSA and growth hormone are bonded directly or through a peptide linker, the compound "human serum albumin-hGH fusion protein (HSA-hGH fusion protein)" can also be referred to as "human serum albumin fused hGH (HSA fused hGH)." The same applies to human serum albumin mutant-hGH fusion protein (HSA mutant-hGH fusion protein).

[0022] In the present invention, when HSA and growth hormone are bound via a peptide linker, the linker is preferably composed of 1 to 50, more preferably 1 to 17, even more preferably 1 to 10, and even more preferably 1 to 6 amino acid residues, and is, for example, composed of 2 to 17, 2 to 10, 10 to 40, 20 to 34, 23 to 31, or 25 to 29 amino acids, and further, for example, composed of only one amino acid residue, or 2, 3, 5, 6, or 20 amino acid residues. As long as the HSA portion bound by the peptide linker retains the function of HSA and the growth hormone portion can exert the physiological activity of growth hormone under physiological conditions, there is no limitation on the amino acid residues or amino acid sequence constituting the peptide linker, but it is preferably composed of glycine and serine. Preferred examples of peptide linkers include those consisting of one glycine, one serine, Gly-Ser, Gly-Gly-Ser, Gly-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 4), Gly-Gly-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 5), and Ser-Gly-Gly-Gly-Gly-Gly-Gly (SEQ ID NO: 6), as well as those containing these amino acid sequences. Those having a sequence in which any one of these amino acid sequences occurs 2 to 10 times or 2 to 5 times in succession can also be preferably used as peptide linkers, and those having a sequence in which any two or more of these amino acid sequences are combined and occur 1 to 10 times or 2 to 5 times in succession can also be preferably used as peptide linkers. A suitable peptide linker that combines two or more of these amino acid sequences is one that contains a total of 20 amino acid sequences consisting of the amino acid sequence Gly-Ser followed by three consecutive amino acid sequences Gly-Gly-Gly-Gly-Gly-Ser (sequence number 5).

[0023] A common method for linking two different polypeptides is, for example, to create an expression vector incorporating DNA in which a gene encoding one polypeptide is linked in-frame downstream of a gene encoding the other polypeptide, and then to express the protein as a recombinant fusion protein by culturing a host cell transformed with this expression vector, which can be used in the present invention.

[0024] When HSA-hGH fusion protein is produced by expressing it as a recombinant in a transformed cell, a fusion protein is obtained in which a polypeptide comprising the amino acid sequence of growth hormone is bound to either the N-terminus or C-terminus of a polypeptide comprising the amino acid sequence of HSA. HSA-hGH fusion protein produced using gene recombination technology is specifically called recombinant HSA-hGH fusion protein.

[0025] When a polypeptide comprising the amino acid sequence of growth hormone is linked to the N-terminus of a polypeptide comprising the amino acid sequence of HSA, an expression vector is used in which DNA is incorporated in which a gene encoding a polypeptide comprising the amino acid sequence of HSA is linked in-frame downstream of a gene encoding a polypeptide comprising the amino acid sequence of growth hormone. When two polypeptides are indirectly linked via a peptide linker, a DNA sequence encoding the linker is inserted in-frame between the genes encoding the two polypeptides.

[0026] When a polypeptide containing the amino acid sequence of growth hormone is linked to the C-terminus of a polypeptide containing the amino acid sequence of HSA, an expression vector is used in which DNA is incorporated in which a gene encoding a polypeptide containing the amino acid sequence of HSA is linked in-frame upstream of a gene encoding a polypeptide containing the amino acid sequence of growth hormone. When two polypeptides are indirectly linked via a peptide linker, a DNA sequence encoding the linker is inserted in-frame between the genes encoding the two polypeptides.

[0027] To produce HSA-hGH fusion protein in a host cell, an expression vector incorporating DNA encoding any of them is introduced into the host cell. The host cell that can be used for this purpose is not particularly limited as long as it is capable of expressing HSA-hGH fusion protein by introducing such an expression vector, and may be any of eukaryotic cells such as mammalian cells, yeast, plant cells, and insect cells, and prokaryotic cells such as Escherichia coli and Bacillus subtilis, but mammalian cells are particularly preferred. However, when expressing as a glycosylated protein, the host cell is selected from eukaryotic cells such as mammalian cells, yeast, plant cells, and insect cells. The Asn residue in the sequence portion represented by Asn-Tyr-Thr, which is usually generated when the 320th amino acid residue of wild-type HSA becomes threonine, or the Asn residue in the sequence represented by Asn-X-Thr (where "X" is an amino acid residue other than proline), is N-linked glycosylated by expressing HSA-hGH fusion protein in a eukaryotic cell.

[0028] When mammalian cells are used as host cells, the type of mammalian cells is not particularly limited, but cells derived from humans, mice, or Chinese hamsters are preferred, and in particular, CHO cells derived from Chinese hamster ovary cells or NS / 0 cells derived from mouse myeloma are preferred. In this case, the expression vector used to incorporate and express the DNA fragment encoding the HSA-hGH fusion protein can be used without any particular limitation as long as it brings about the expression of the gene when introduced into a mammalian cell. The gene incorporated in the expression vector is placed downstream of a DNA sequence (gene expression control site) that can regulate the frequency of gene transcription in a mammalian cell. Examples of gene expression control sites that can be used in the present invention include a promoter derived from cytomegalovirus, an SV40 early promoter, a human elongation factor-1α (EF-1α) promoter, and a human ubiquitin C promoter.

[0029] Mammalian cells into which such expression vectors have been introduced begin to express the proteins incorporated in the expression vectors, but the expression levels vary from cell to cell, and are not uniform. Therefore, in order to efficiently produce HSA-hGH fusion protein, a step is required to select cells with high expression levels from among the mammalian cells into which the expression vectors have been introduced. To perform this selection step, a gene that acts as a selection marker is incorporated into the expression vector.

[0030] The most common selection markers are enzymes (drug resistance markers) that break down drugs such as puromycin and neomycin. Mammalian cells usually die in the presence of these drugs at a certain concentration or higher. However, mammalian cells that have been introduced with an expression vector incorporating a drug resistance marker gene can detoxify or attenuate the above drug by the expressed drug resistance marker, and can survive even in the presence of the above drug. By introducing an expression vector incorporating a drug resistance marker as a selection marker into mammalian cells and continuing to culture the cells in a selection medium containing a drug corresponding to the drug resistance marker, for example, while gradually increasing the concentration of the drug, cells that can grow even in the presence of a higher concentration of the drug can be obtained. In the cells selected in this way, the expression level of the gene encoding the target protein incorporated in the expression vector generally increases along with the drug resistance marker, and as a result, cells with a high expression level of the protein are selected.

[0031] Glutamine synthetase (GS) can also be used as a selection marker. Glutamine synthetase is an enzyme that synthesizes glutamine from glutamic acid and ammonia. When mammalian cells are cultured in a selection medium that contains an inhibitor of glutamine synthetase, such as L-methionine sulfoximine (MSX), but does not contain glutamine, the cells usually die. However, when an expression vector incorporating glutamine synthetase as a selection marker is introduced into mammalian cells, the expression level of glutamine synthetase increases in the cells, making them capable of growing even in the presence of higher concentrations of MSX. In this case, if the culture is continued while gradually increasing the concentration of MSX, cells capable of growing even in the presence of higher concentrations of MSX can be obtained. In the cells selected in this way, the expression level of the gene encoding the target protein incorporated into the expression vector generally increases along with glutamine synthetase, and as a result, cells with a high expression level of the protein are selected.

[0032] Dihydrofolate reductase (DHFR) can also be used as a selection marker. When DHFR is used as a selection marker, mammalian cells into which an expression vector has been introduced are cultured in a selection medium containing a DHFR inhibitor such as methotrexate or aminopterin. By continuing the culture while gradually increasing the concentration of the DHFR inhibitor, cells that can grow even in the presence of a higher concentration of the DHFR inhibitor can be obtained. The selection medium used in this case preferably does not contain hypoxanthine or thymidine. In the cells selected in this manner, the expression level of the gene encoding the target protein incorporated into the expression vector, together with DHFR, generally increases, and as a result, cells with a high expression level of the protein are selected.

[0033] Expression vectors are known in which glutamine synthetase (GS) is placed as a selection marker downstream of a gene encoding a protein of interest via an internal ribosome entry site (IRES) (International Patent Publications WO2012 / 063799, WO2013 / 161958). The expression vectors described in these publications are particularly suitable for use in producing HSA-hGH fusion proteins.

[0034] For example, an expression vector for expressing a target protein, which comprises a first gene expression control site, a gene encoding the protein downstream thereof, an internal ribosome binding site further downstream thereof, and a gene encoding glutamine synthetase further downstream thereof, and further comprises a dihydrofolate reductase gene or a drug resistance gene downstream of the first gene expression control site or a second gene expression control site different from the first gene expression control site, can be suitably used for producing an HSA-hGH fusion protein. In this expression vector, as the first gene expression control site or the second gene expression control site, a promoter derived from cytomegalovirus, an SV40 early promoter, a human elongation factor-1α promoter (hEF-1α promoter), or a human ubiquitin C promoter is suitably used, with the hEF-1α promoter being particularly suitable.

[0035] As the internal ribosome binding site, those derived from the 5' untranslated region of the genome of a virus selected from the group consisting of Picornaviridae virus, foot and mouth disease virus, hepatitis A virus, hepatitis C virus, coronavirus, bovine enterovirus, Theiler's murine encephalomyelitis virus, and Coxsackie B virus, or a gene selected from the group consisting of human immunoglobulin heavy chain binding protein gene, Drosophila antennapedia gene, and Drosophila ultravithorax gene, are preferably used, but an internal ribosome binding site derived from the 5' untranslated region of the mouse encephalomyocarditis virus genome is particularly preferable. When using an internal ribosome binding site derived from the 5' untranslated region of the mouse encephalomyocarditis virus genome, in addition to the wild type, those in which some of the multiple initiation codons contained in the wild type internal ribosome binding site have been destroyed can also be preferably used. In addition, the drug resistance gene preferably used in this expression vector is preferably a puromycin or neomycin resistance gene, and more preferably a puromycin resistance gene.

[0036] Also, for example, an expression vector for expressing a target protein, which comprises a human elongation factor-1α promoter, a gene encoding the protein downstream thereof, an internal ribosome binding site derived from the 5' untranslated region of the mouse encephalomyocarditis virus genome further downstream thereof, and a gene encoding glutamine synthetase further downstream thereof, and further comprises another gene expression control site and a dihydrofolate reductase gene downstream thereof, in which the internal ribosome binding site is an internal ribosome binding site in which a part of the multiple initiation codons contained in the wild-type internal ribosome binding site has been destroyed, can be suitably used for producing an HSA-hGH fusion protein. Examples of such expression vectors include the expression vectors described in WO2013 / 161958.

[0037] In addition, for example, an expression vector for expressing a target protein, which comprises a human elongation factor-1α promoter, a gene encoding the protein downstream thereof, an internal ribosome binding site derived from the 5' untranslated region of the mouse encephalomyocarditis virus genome further downstream thereof, and a gene encoding glutamine synthetase further downstream thereof, and further comprises another gene expression control site and a drug resistance gene downstream thereof, in which the internal ribosome binding site is an internal ribosome binding site in which a part of the multiple initiation codons contained in the wild-type internal ribosome binding site is destroyed, can be suitably used for producing an HSA-hGH fusion protein. Examples of such expression vectors include pE-mIRES-GS-puro described in WO2012 / 063799 and pE-mIRES-GS-mNeo described in WO2013 / 161958.

[0038] There are three initiation codons (ATG) at the 3' end of the internal ribosome binding site derived from the 5' untranslated region of the wild-type murine encephalomyocarditis virus genome, and the sequence portion including the three initiation codons is shown in SEQ ID NO: 7 (5'-ATGataatATGgccacaaccATG-3': the initiation codon ATG is shown in uppercase). An example of a portion of the initiation codon in this sequence portion that has been destroyed is shown in SEQ ID NO: 8 (5'-atgataagcttgccacaaccatg-3'), and the above pE-mIRES-GS-puro and pE-mIRES-GS-mNeo are expression vectors having an IRES including the sequence shown in SEQ ID NO: 8.

[0039] In the present invention, mammalian cells into which an expression vector incorporating a DNA fragment encoding an HSA-hGH fusion protein has been introduced are selectively cultured in a selective medium in order to select cells with high expression levels.

[0040] In the selective culture, when DHFR is used as a selective marker, the concentration of the DHFR inhibitor contained in the selective medium is increased stepwise. When the DHFR inhibitor is methotrexate, the maximum concentration is preferably 0.25 to 5 μM, more preferably 0.5 to 1.5 μM, and even more preferably about 1.0 μM.

[0041] When GS is used as a selection marker, the concentration of the GS inhibitor contained in the selection medium is increased stepwise. When the GS inhibitor is MSX, the maximum concentration is preferably 10 to 1000 μM, for example, 20 to 500 μM, 20 to 80 μM, or 20 to 30 μM. In this case, a medium that does not contain glutamine is generally used as the selection medium.

[0042] When an enzyme that decomposes puromycin is used as a selection marker, the maximum concentration of puromycin contained in the selection medium is preferably 3 to 30 μg / mL, more preferably 5 to 20 μg / mL, and even more preferably about 10 μg / mL.

[0043] When an enzyme that decomposes neomycin is used as a selection marker, the maximum concentration of G418 contained in the selection medium is preferably 0.1 to 2 mg / mL, more preferably 0.5 to 1.5 mg / mL, and even more preferably about 1 mg / mL.

[0044] Furthermore, as a medium for culturing mammalian cells, both the medium used in selective culture and the medium used to produce recombinant proteins (recombinant protein production medium) described below can be used without any particular limitations as long as it is capable of culturing and growing mammalian cells, but preferably a serum-free medium is used. Since HSA has the property of adsorbing components contained in serum, when HSA is produced using a medium containing serum, HSA that has adsorbed impurities in serum is obtained, and it becomes necessary to remove these impurities in a subsequent process.

[0045] In the present invention, the HSA-hGH fusion protein is obtained by culturing cells expressing these proteins in a serum-free medium. By using a serum-free medium, the amount of impurities adsorbed to the HSA-hGH fusion protein can be reduced, and the subsequent purification process can be simplified.

[0046] The cells with high expression levels of HSA-hGH fusion protein selected by selective culture are used to produce HSA-hGH fusion protein (HSA-hGH fusion protein producing cells). HSA-hGH fusion protein is produced by culturing HSA-hGH fusion protein producing cells in a medium for HSA-hGH fusion protein production. This culture is called production culture.

[0047] In the present invention, the serum-free medium used as the medium for producing the HSA-hGH fusion protein is preferably a medium containing, for example, 3 to 700 mg / L amino acids, 0.001 to 50 mg / L vitamins, 0.3 to 10 g / L monosaccharides, 0.1 to 10,000 mg / L inorganic salts, 0.001 to 0.1 mg / L trace elements, 0.1 to 50 mg / L nucleosides, 0.001 to 10 mg / L fatty acids, 0.01 to 1 mg / L biotin, 0.1 to 20 μg / L hydrocortisone, 0.1 to 20 mg / L insulin, 0.1 to 10 mg / L vitamin B12, 0.01 to 1 mg / L putrescine, 10 to 500 mg / L sodium pyruvate, and a water-soluble iron compound. If desired, thymidine, hypoxanthine, conventional pH indicators, antibiotics, etc. may be added to the medium.

[0048] As a serum-free medium used as a medium for producing HSA-hGH fusion protein, DMEM / F12 medium (a mixed medium of DMEM and F12) may be used as a basic medium, and these media are well known to those skilled in the art. Furthermore, as a serum-free medium, DMEM (HG) HAM Improved (R5) medium, which contains sodium bicarbonate, L-glutamine, D-glucose, insulin, sodium selenite, diaminobutane, hydrocortisone, ferrous sulfate (II), asparagine, aspartic acid, serine, and polyvinyl alcohol, may be used. Furthermore, commercially available serum-free media, such as CD OptiCHO TM Culture medium, CHO-S-SFM II medium or CD CHO medium (Thermo Fisher Scientific), IS cho-V TM Culture medium (Irvine Scientific), EX-CELL TM 302 medium, EX-CELL TM Advanced medium or EX-CELL TM 325-PF medium (SAFC Biosciences) or the like can also be used as the basal medium.

[0049] The medium for producing HSA-hGH fusion protein may be appropriately supplemented with 1 to 50 g / L (e.g., 1 to 5 g / L) of hydrolysate derived from plants such as soybean, wheat, rice, etc. The most commonly used is a protein hydrolysate derived from soybean. However, the HSA-hGH fusion protein can be produced without adding a hydrolysate derived from a plant such as rice, for example, a protein hydrolysate derived from soybean, to the medium for producing HSA-hGH fusion protein.

[0050] After the production culture is completed, the culture medium is subjected to a chromatography step for purifying the HSA-hGH fusion protein. However, what is subjected to the chromatography step is the culture supernatant from which cells and other substances have been removed. Methods for obtaining the culture supernatant from the culture medium include filtration using a membrane filter and centrifugation.

[0051] In the present invention, each of the chromatographic steps for purifying the HSA-hGH fusion protein may be carried out in the presence of a non-ionic surfactant, if necessary, to prevent non-specific adsorption of the protein. There is no particular limitation on which non-ionic surfactant is used, but a polysorbate surfactant is preferably used, more preferably polysorbate 80 or polysorbate 20. The concentration of such a non-ionic surfactant is preferably 0.005% (w / v) to 0.1% (w / v), more preferably 0.005% (w / v) to 0.05% (w / v), for example, 0.01% (w / v), 0.05% (w / v), etc.

[0052] The purification process of the HSA-hGH fusion protein can be carried out at room temperature or at a low temperature, but is preferably carried out at a low temperature, particularly at 1 to 10°C.

[0053] In one embodiment of the present invention, the purification process of the HSA-hGH fusion protein includes a column chromatography step using a material having an affinity for the HSA-hGH fusion protein bound to it as a stationary phase, a column chromatography step using a material having an affinity for phosphate groups as a stationary phase, a cation exchange column chromatography step, and a size exclusion column chromatography step. However, one or more chromatography steps can be added to these chromatography steps. Such additional chromatography steps include, for example, a column chromatography step using a material having an affinity for the HSA-hGH fusion protein bound to it as a stationary phase, a column chromatography step using a material having an affinity for phosphate groups as a stationary phase, a cation exchange column chromatography step, an anion exchange column chromatography step, a hydrophobic column chromatography step, a dye affinity column chromatography step, and a size exclusion column chromatography step.

[0054] In one embodiment of the present invention, the purification process of the HSA-hGH fusion protein includes, in this order, a column chromatography step using a material having an affinity for the HSA-hGH fusion protein bound to it as a stationary phase, a column chromatography step using a material having an affinity for phosphate groups as a stationary phase, a cation exchange column chromatography step, and a size exclusion column chromatography step. However, one or more chromatography steps can be added to these chromatography steps. Such additional chromatography steps include, for example, a column chromatography step using a material having an affinity for the HSA-hGH fusion protein bound to it as a stationary phase, a column chromatography step using a material having an affinity for phosphate groups as a stationary phase, a cation exchange column chromatography step, an anion exchange column chromatography step, a hydrophobic column chromatography step, a dye ligand column chromatography step, and a size exclusion column chromatography step. The additional chromatography step can be added between any adjacent steps, or can be added as the first or last chromatography step.

[0055] In one embodiment of the present invention, the purification process includes, in this order, a column chromatography step using as the stationary phase a material to which an antibody having affinity for the HSA-hGH fusion protein is bound, a column chromatography step using as the stationary phase a material having affinity for phosphate groups, a cation exchange column chromatography step, and a size exclusion column chromatography step. The process is described in detail below.

[0056] The first column chromatography step uses column chromatography using a material to which an antibody having affinity for the HSA-hGH fusion protein is bound as a stationary phase. Here, the antibody may have affinity for either HSA or hGH, but is preferably one that has affinity for hGH. For example, Capture select Human Growth Hormone Affinity Matrix (Thermo Fisher Scientific), which contains a carrier to which an antibody against human growth hormone is bound, can be suitably used.

[0057] When using a column chromatography column using a material bound to an antibody having affinity for hGH as a stationary phase, the HSA-hGH fusion protein is applied to a column previously equilibrated with a buffer solution. There is no particular limitation on the type of buffer solution, but a Tris-HCl buffer solution is preferred, and its concentration is preferably 5 to 50 mM, more preferably 10 to 30 mM. The pH is preferably adjusted to 6.7 to 7.3, more preferably 6.9 to 7.1, and even more preferably about 7.0. The HSA-hGH fusion protein is preferably eluted from the column using glycine-hydrochloric acid. The concentration of glycine-hydrochloric acid is preferably 20 to 100 mM, more preferably 40 to 60 mM, and even more preferably about 50 mM. The pH is preferably adjusted to 2.0 to 4.0, more preferably 2.8 to 3.2, and even more preferably about 3.0. The pH of the eluate is immediately adjusted to near neutral, for example, pH 6.4 to 7.0.

[0058] The second column chromatography step uses a material having affinity for phosphate groups as a stationary phase. Hydroxyapatite column chromatography and fluoroapatite column chromatography are suitable as column chromatography using a material having affinity for phosphate groups as a stationary phase, with hydroxyapatite column chromatography being particularly preferred. These are intended to remove impurities by utilizing the interactions of both metal affinity due to calcium ions and cation exchange due to phosphate groups.

[0059] The use of hydroxyapatite column chromatography will be described in detail below. There is no particular limitation on the carrier used in hydroxyapatite chromatography, and it may be ceramic or crystalline, but one particularly preferred carrier is CHT Type II, 40 μm (Bio-Rad Laboratories).

[0060] The pH and electrical conductivity of the eluate obtained in the first column chromatography step are adjusted before being applied to the hydroxyapatite chromatography column. At this time, the pH is adjusted to preferably 6.5 to 7.5, more preferably 6.8 to 7.2, and even more preferably 6.9 to 7.1. The electrical conductivity is adjusted to preferably 0.4 to 0.8 S / m, and more preferably 0.5 to 0.7 S / m.

[0061] The eluate with adjusted pH and conductivity is applied to a hydroxyapatite chromatography column previously equilibrated with a buffer solution. There is no particular limitation on the type of buffer solution, but MES buffer solution is preferred, and its concentration is preferably 5 to 50 mM, more preferably 10 to 30 mM, for example 20 mM. The pH is preferably adjusted to 6.7 to 7.3, more preferably 6.9 to 7.1, and even more preferably about 7.0. The buffer solution contains phosphate ions, and its concentration is preferably 0 to 3 mM, more preferably 0 to 2 mM, for example 1 mM.

[0062] The HSA-hGH fusion protein is eluted from the hydroxyapatite chromatography column using a buffer solution having an increased concentration of phosphate ions, the concentration of which is preferably 20 to 50 mM, more preferably 25 to 40 mM, and even more preferably 25 to 35 mM, for example 30 mM.

[0063] The third column chromatography step uses cation exchange column chromatography to remove contaminating proteins. There is no particular limitation on which cation exchange resin is used in the cation exchange column chromatography, but a weak cation exchange resin is preferred, and more preferably a weak cation exchange resin having selectivity based on both hydrophobic interaction and hydrogen bond formation. For example, a weak cation exchange resin having a phenyl group, an amide bond, and a carboxyl group and having selectivity based on hydrophobic interaction and hydrogen bond formation, such as Capto MMC (GE Healthcare), can be suitably used.

[0064] The pH and electrical conductivity of the eluate obtained in the second column chromatography step are adjusted before it is subjected to cation exchange column chromatography. At this time, the pH is adjusted to preferably 5.3 to 6.2, more preferably 5.4 to 6.1, and even more preferably 5.6 to 5.8. The electrical conductivity is adjusted to preferably 0.5 to 0.9 S / m, and more preferably 0.6 to 0.8 S / m.

[0065] The eluate with adjusted pH and conductivity is subjected to cation exchange column chromatography equilibrated with a buffer solution in advance. There is no particular limitation on the type of buffer solution, but MES buffer solution is preferred, and its concentration is preferably 30 to 70 mM, more preferably 40 to 60 mM, for example 50 mM. The pH is preferably adjusted to 5.4 to 6.0, more preferably 5.6 to 5.8, for example 5.7. The buffer solution contains a salt, and when the salt is a neutral salt, its concentration in the buffer solution is preferably 30 to 150 mM, more preferably 50 to 120 mM, even more preferably 80 to 120 mM, for example 100 mM. The neutral salt in this case is preferably sodium chloride or potassium chloride, and particularly preferably sodium chloride.

[0066] The elution of the HSA-hGH fusion protein from the cation exchange column chromatography is carried out using a buffer solution having an increased concentration of a neutral salt, the concentration of which is preferably 400 to 600 mM, more preferably 500 to 600 mM, even more preferably 530 to 570 mM, for example 550 mM.

[0067] The fourth column chromatography step uses size exclusion chromatography to remove contaminants based on molecular size, particularly small molecular contaminants such as endotoxins, multimers and degradation products of the HSA-hGH fusion protein.

[0068] In the size exclusion chromatography step, the column is equilibrated in advance. Here, the type of buffer is not particularly limited, but a phosphate buffer is preferred, and its concentration is preferably 5 to 20 mM, more preferably 8 to 12 mM, for example 10 mM. The pH is preferably adjusted to 6.6 to 7.4, more preferably 7.0 to 7.4, for example 7.2. The buffer may also contain a disaccharide that can be used as a pharmaceutical additive. Such a disaccharide is preferably sucrose, and its concentration is preferably 60 to 90 mg / mL, more preferably 70 to 80 mg / mL, for example 75 mg / mL. A substantially pure HSA-hGH fusion protein is obtained by the first to fourth column chromatography steps.

[0069] In the purification process of HSA-hGH fusion protein, a virus inactivation step can be added as desired. The virus inactivation step can be performed between any two chromatography steps, or can be performed before the first chromatography step or after the last chromatography step. In addition, the virus inactivation step can be performed once, twice, or three or more times in the purification process of HSA-hGH fusion protein.

[0070] When the chromatography step includes a column chromatography step (first column chromatography step) using a material having an affinity for HSA-hGH fusion protein bound thereto as a stationary phase, a column chromatography step (second column chromatography step) using a material having affinity for phosphate groups as a stationary phase, a cation exchange column chromatography step (third column chromatography step), and a size exclusion column chromatography step (fourth column chromatography step) in this order, the virus inactivation step is preferably carried out between the first column chromatography step and the second column chromatography step, or / and after the fourth column chromatography step. There is no particular limitation on which virus inactivation step is applied, but the solvent-surfactant method or the filter filtration method can be preferably applied. The solvent-surfactant method is a method in which an organic solvent and a surfactant are added to a solution in which the virus is to be inactivated, thereby inactivating the virus. When the solvent-surfactant method is applied, an organic solvent and a nonionic surfactant are added to a solution containing the HSA-hGH fusion protein, mixed, and the mixture is incubated, for example, for more than 3 hours. The solution used in the solvent-detergent method is not particularly limited as long as it keeps the HSA-hGH fusion protein stable for at least 2 hours, but a glycine buffer, phosphate buffer, MES buffer, Tris-HCl buffer, or a mixture of these with an organic solvent and a non-detergent, whose pH is adjusted to near neutral, can be preferably used. There is also no particular limitation on which non-ionic detergent to use, but for example, polysorbate 20, polysorbate 80, and triton X-100 can be used alone or in any combination. Polysorbate 80 is one of the particularly suitable non-ionic detergents, and can be used alone or in combination with other non-ionic detergents. There is also no particular limitation on which organic solvent to use, but for example, tri(n-butyl phosphate) can be used.When polysorbate 80 and tri(n-butyl phosphate) are used in combination, the concentration of polysorbate 80 in the mixture is 0.3-2%, e.g., 1%, and the concentration of tri(n-butyl phosphate) is 0.1-0.5%, e.g., 0.3%, and the mixture is incubated for 2-5 hours, e.g., 3 hours.

[0071] The filter filtration method is a method for removing viruses by filtering a solution from which viruses should be removed through a filter membrane (virus removal membrane) that has the ability to remove viruses. The filter membrane used in the filter filtration method preferably has an average pore size of 17 to 21 nm, and is made of, for example, regenerated cellulose. When the filter filtration method is applied, a solution containing HSA-hGH fusion protein is passed through the virus removal membrane. For example, viruses can be more reliably removed by performing virus inactivation using a solvent-surfactant method between the first and second column chromatography steps, and performing virus inactivation using the filter filtration method after the fourth column chromatography step.

[0072] The method using a virus removal membrane can also be called a virus removal process, but in the present invention, it can also be called one method of a virus inactivation process.

[0073] In the present invention, the HSA-hGH fusion protein has a higher stability in the blood and a longer half-life than the original growth hormone not bound to HSA. Although it varies depending on the administration route and dosage, the blood half-life (t 1 / 2 β) is extremely stable in the blood, for example, for more than 5 hours. For example, the blood half-life (t 1 / 2 β) was administered subcutaneously in a single dose of 0.5-10 mg / kg to male cynomolgus monkeys, and the blood half-life (t 1 / 2 β) is 5 to 40 hours.

[0074] In the present invention, a medicine comprising an HSA mutant-growth hormone fusion protein as an active ingredient can be administered intravenously, intramuscularly, intraperitoneally or subcutaneously as an injection.

[0075] There are two types of human growth hormone, one with a molecular weight of 22 kDa (22kDa human growth hormone, referred to herein as 22K human growth hormone) and one with a molecular weight of 20 kDa (20kDa human growth hormone, referred to herein as 20K human growth hormone). 22K growth hormone is a protein consisting of 191 amino acids and has the amino acid sequence shown in SEQ ID NO:9. Usually, when "human growth hormone (or hGH)" is mentioned, this 22K growth hormone is meant, but in this specification, when "human growth hormone (or hGH)" is simply mentioned, it includes both 22K human growth hormone and 20K human growth hormone.

[0076] In this specification, the term "22K human growth hormone (or 22KhGH)" includes not only wild-type 22KhGH having the amino acid sequence shown in SEQ ID NO:9, but also 22KhGH mutants having growth-promoting activity in which one or more amino acids have been substituted, deleted and / or added. The number of amino acids that may be substituted, deleted and / or added is preferably 1 to 8, more preferably 1 to 4, and even more preferably 1 to 2 for each mutation type. Here, the amino acid sequence of the 22KhGH mutant has preferably 85% or more identity, more preferably 90% or more identity, and even more preferably 95% or more identity with the amino acid sequence of the wild-type 22KhGH shown in SEQ ID NO:9.

[0077] Wild-type 20K human growth hormone is a protein having growth-promoting activity, which corresponds to a deletion of 15 amino acids, 32nd to 46th, counting from the N-terminus, of the 191 amino acids constituting wild-type 22K growth hormone (SEQ ID NO: 9), and is composed of an amino acid sequence (SEQ ID NO: 10) consisting of 176 amino acids. However, in this specification, when simply referring to "20K human growth hormone (or 20KhGH)", in addition to the wild-type 20KhGH shown in SEQ ID NO: 10, it also includes a mutant of 20KhGH having growth-promoting activity, which corresponds to the sequence in which one or more amino acids have been substituted, deleted and / or added. The number of amino acids that may be substituted, deleted and / or added is preferably 1 to 8, more preferably 1 to 4, and even more preferably 1 to 2 for each mutation type. Here, the amino acid sequence of the 20KhGH mutant preferably has 85% or more identity, more preferably 90% or more identity, and even more preferably 95% or more identity to the amino acid sequence of the wild-type 20KhGH shown in sequence number 10.

[0078] In the present invention, the position and type (deletion, substitution, addition) of each mutation in various hGH mutants compared to normal wild-type hGH can be easily confirmed by aligning the amino acid sequences of both hGH. In the present invention, the identity between the amino acid sequence of wild-type hGH and the amino acid sequence of hGH with mutations can be easily calculated using a well-known homology calculation algorithm. For example, such algorithms include BLAST (Altschul SF. J Mol. Biol. 215. 403-10, (1990)), Pearson and Lipman's similarity search method (Proc. Natl. Acad. Sci. USA. 85. 2444 (1988)), Smith and Waterman's local homology algorithm (Adv. Appl. Math. 2. 482-9 (1981)), etc.

[0079] Substitutions of amino acids in the above amino acid sequence of hGH with other amino acids occur within amino acid families that are related, for example, by their side chains and chemical properties. Substitutions within such amino acid families are not expected to significantly alter the function of hGH (i.e., are conservative amino acid substitutions). Examples of such amino acid families include: (1) The acidic amino acids aspartic acid and glutamic acid, (2) The basic amino acids histidine, lysine, and arginine (3) Aromatic amino acids such as phenylalanine, tyrosine, tryptophan, (4) Serine and threonine, which are amino acids that have hydroxyl groups (hydroxyamino acids), (5) The hydrophobic amino acids methionine, alanine, valine, leucine, and isoleucine, (6) The neutral hydrophilic amino acids cysteine, serine, threonine, asparagine, and glutamine, (7) Glycine and proline, which are amino acids that affect the orientation of peptide chains, (8) Asparagine and glutamine, which are amide amino acids (polar amino acids), (9) The aliphatic amino acids alanine, leucine, isoleucine, and valine, (10) The amino acids with small side chains, alanine, glycine, serine, and threonine, (11) Alanine and glycine, amino acids with particularly small side chains.

[0080] Preparations containing hGH with a molecular weight of about 22KD as an active ingredient, which is produced as a recombinant protein using Escherichia coli with an hGH gene introduced therein (hGH preparations), are widely used clinically as a treatment for short stature due to growth hormone deficiency, short stature in Turner syndrome, short stature due to SGA, short stature in Noonan syndrome, short stature due to chronic renal failure, short stature in Prader-Willi syndrome, and short stature in chondrodystrophy. hGH preparations are particularly effective in cases where epiphyseal closure is not present in these diseases. When administered subcutaneously or intramuscularly, the hGH component circulates in the blood, and its growth-promoting activity promotes the growth of the patient. hGH preparations are also widely used clinically as a treatment for adult growth hormone deficiency. Patients with adult growth hormone deficiency have abnormal lipid metabolism, but administration of hGH preparations normalizes the lipid metabolism of the patient, improving the patient's QOL. Growth hormone is also used clinically as a treatment for wasting caused by AIDS. An example of an hGH preparation for short stature due to growth hormone deficiency, adult growth hormone deficiency, etc. is Growject (registered trademark).

[0081] When producing a fusion protein between an HSA mutant and hGH, a specific method for linking a polypeptide containing the amino acid sequence of an HSA mutant to a polypeptide containing the amino acid sequence of hGH is, for example, to create an expression vector incorporating a DNA fragment in which a gene encoding one of the polypeptides is linked in-frame to a gene encoding the other polypeptide downstream of the gene encoding the other polypeptide, and then culturing a host cell transformed with this expression vector to express it as a recombinant protein, a method that can be generally used in the present invention.

[0082] When a fusion protein of HSA mutant and hGH is produced by expressing it as a recombinant protein in a transformed cell, a polypeptide containing the amino acid sequence of hGH is linked directly or indirectly via a linker to either the N-terminus or C-terminus of a polypeptide containing the amino acid sequence of the HSA mutant.

[0083] When a polypeptide containing the amino acid sequence of hGH is linked to the N-terminus of a polypeptide containing the amino acid sequence of an HSA mutant, an expression vector is used in which a DNA fragment is incorporated in which a gene encoding a polypeptide containing the amino acid sequence of an HSA mutant is linked in-frame downstream of a gene encoding a polypeptide containing the amino acid sequence of hGH. When two polypeptides are indirectly linked via a peptide linker, a DNA sequence encoding the linker is placed in-frame between the genes encoding the two polypeptides.

[0084] When a polypeptide containing the amino acid sequence of hGH is linked to the C-terminus of a polypeptide containing the amino acid sequence of an HSA mutant, an expression vector is used in which a DNA fragment is incorporated in which a gene encoding a polypeptide containing the amino acid sequence of an HSA mutant is linked in-frame upstream of a gene encoding a polypeptide containing the amino acid sequence of hGH. When two polypeptides are indirectly linked via a peptide linker, a DNA sequence encoding the linker is placed in-frame between the genes encoding the two polypeptides.

[0085] In the present invention, a preferred example of a fusion protein of an HSA mutant and hGH (a type of HSA-hGH fusion protein) is an HSA-hGH fusion protein having the amino acid sequence shown in SEQ ID NO: 11, which is obtained by binding the C-terminus of 22K human growth hormone having the amino acid sequence shown in SEQ ID NO: 9 by peptide bond without a linker to the N-terminus of HSA (A320T) having the amino acid sequence shown in SEQ ID NO: 3. In the present invention, the binding of HSA (A320T) and 22K hGH in this order is called "22K human growth hormone-mHSA" or "22KhGH-mHSA." Similarly, the binding of the N-terminus of 22K human growth hormone by peptide bond without a linker to the C-terminus of HSA (A320T) is called "mHSA-22K human growth hormone" or "mHSA-22KhGH."

[0086] Furthermore, the HSA-hGH fusion protein having the amino acid sequence shown in SEQ ID NO:12, which is obtained by binding the C-terminus of 20K human growth hormone having the amino acid sequence shown in SEQ ID NO:10 by a peptide bond without a linker to the N-terminus of human serum albumin (A320T) having the amino acid sequence shown in SEQ ID NO:3, is called "20K human growth hormone-mHSA" or "20KhGH-mHSA." Similarly, the HSA-hGH fusion protein having the N-terminus of 20K human growth hormone bound by a peptide bond without a linker to the C-terminus of human serum albumin (A320T) is called "mHSA-20K human growth hormone" or "mHSA-20KhGH."

[0087] In the present invention, the HSA-hGH fusion protein has a blood half-life (t 1 / 2 The half-life (t β) of mHSA-22KhGH and 22KhGH-mHSA in the blood is approximately 5 hours or more, and is extremely stable in the blood. Although it varies depending on the dosage, for example, when a single dose of 4 mg / kg is administered subcutaneously to a male cynomolgus monkey, the half-life (t 1 / 2 β) is 20 to 35 hours.

[0088] The HSA-hGH fusion protein of the present invention can be used as a medicine, and can make the functions of human growth hormone and HSA cooperate in vivo.

[0089] The HSA-hGH fusion protein of the present invention is extremely stable in blood. Therefore, according to the present invention, human growth hormone can be stabilized in blood and can remain in the blood in a state where it maintains its activity for a long period of time. Therefore, when the fusion protein is used as a medicine, it becomes possible to reduce the administration frequency and / or dosage compared to human growth hormone. For example, human growth hormone needs to be administered every day, but the fusion protein can be administered at a frequency of, for example, every 3 to 30 days. In addition, it becomes possible to reduce the total dosage of the medicine during the treatment period, for example, to 1 / 3 or less (for example, 1 / 3 to 1 / 10) in molar ratio.

[0090] The HSA-hGH fusion protein of the present invention can be used as a medicine for diseases such as short stature due to growth hormone deficiency, short stature in Turner syndrome, short stature due to chronic renal failure, short stature in Prader-Willi syndrome, short stature in chondrodystrophy, short stature due to SGA, or short stature in Noonan syndrome. hGH preparations are particularly effective in these diseases when epiphyseal closure is not involved. In addition, the HSA-hGH fusion protein of the present invention can be used as a medicine for diseases such as adult growth hormone deficiency, wasting due to AIDS, and wasting due to anorexia, but is not limited to these. It can also be used as a therapeutic agent for diseases whose symptoms can be improved by long-term action of the physiological activities of growth hormone, such as growth promotion activities such as promotion of cartilage formation and promotion of protein assimilation, and body composition and lipid metabolism improvement.

[0091] There is no particular limitation on the dosage and administration of 22K hGH-mHSA when administered to humans for therapeutic purposes, as long as the pharmacological effect of hGH is demonstrated. The dosage and administration of 22K hGH-mHSA is exemplified below, but the dosage and administration is not limited to these.

[0092] When 22KhGH-mHSA is administered to a patient with short stature due to growth hormone deficiency without epiphyseal closure, the preferred dose per administration is 0.01-0.7 mg / kg body weight. When 22KhGH-mHSA is administered to a patient with short stature due to Turner syndrome without epiphyseal closure, the preferred dose per administration is 0.015-1.4 mg / kg body weight. When 22KhGH-mHSA is administered to a patient with short stature due to chronic renal failure without epiphyseal closure, the preferred dose per administration is 0.01-1.4 mg / kg body weight. When 22KhGH-mHSA is administered to a patient with short stature due to Prader-Willi syndrome without epiphyseal closure, the preferred dose per administration is 0.012-0.98 mg / kg body weight. When 22KhGH-mHSA is administered to a patient with short stature due to chondrodystrophy without epiphyseal closure, the preferred dose per administration is 0.015-1.4 mg / kg body weight. When 22KhGH-mHSA is administered to a patient with SGA short stature without epiphyseal closure, the preferred dose per administration is 0.012-1.9 mg / kg body weight. When 22KhGH-mHSA is administered to a patient with adult growth hormone deficiency, the preferred dose per administration is 0.001-0.34 mg / kg body weight. When 22KhGH-mHSA is administered to a patient with short stature due to Noonan syndrome without epiphyseal closure, the preferred dose per administration is 0.013-1.8 mg / kg body weight. When 22KhGH-mHSA is administered to a patient exhausted by AIDS, the preferred dosage per administration is 0.005-0.4 mg / kg body weight. However, the dosage should be appropriately changed depending on the patient's test findings, etc. In addition, the preferred administration interval of 22KhGH-mHSA in these diseases is once every 7-30 days, and should be appropriately changed to once every 7-14 days, once every 10-20 days, or once every 14-21 days depending on the patient's test findings, etc. In addition, the administration method is preferably subcutaneous injection, intramuscular injection, or intravenous injection, and more preferably subcutaneous injection or intramuscular injection.

[0093] The aqueous pharmaceutical composition of the present invention comprises a protein formed by combining serum albumin and growth hormone as an active ingredient, a preservative, sucrose and a nonionic surfactant as main stabilizers, and a buffer as a pH adjuster.

[0094] The concentration of the protein (particularly 22KhGH-mHSA) bound to serum albumin and growth hormone contained in the aqueous pharmaceutical composition is preferably 10 to 100 mg / mL, more preferably 15 to 70 mg / mL, even more preferably 30 to 65 mg / mL, and even more preferably 40 to 60 mg / mL, for example, 50 mg / mL.

[0095] The preservative contained in the aqueous pharmaceutical composition is not particularly limited as long as it is pharma- ceutical acceptable, but phenol is preferred. When phenol is used as a preservative, the concentration of phenol contained in the aqueous pharmaceutical composition is preferably 0.5 to 12 mg / mL, more preferably 3 to 9 mg / mL, even more preferably 4 to 8 mg / mL, and even more preferably 5 to 7 mg / mL, for example, 6 mg / mL.

[0096] The concentration of sucrose contained in the aqueous pharmaceutical composition is preferably 10 to 150 mg / mL, more preferably 50 to 100 mg / mL, even more preferably 60 to 90 mg / mL, and even more preferably 70 to 80 mg / mL, for example, 75 mg / mL.

[0097] As the nonionic surfactant contained in the aqueous pharmaceutical composition, polysorbate, poloxamer, etc. can be used alone or in combination. As the polysorbate, polysorbate 20 and polysorbate 80 are particularly suitable, and as the poloxamer, poloxamer 188 (polyoxyethylene (160) polyoxypropylene (30) glycol) is particularly suitable. The concentration of the nonionic surfactant contained in the aqueous pharmaceutical composition is preferably 0.15 to 10 mg / mL, more preferably 1.0 to 4.5 mg / mL, even more preferably 1.5 to 4.5 mg / mL, even more preferably 2 to 4 mg / mL, even more preferably 2.5 to 3.5 mg / mL, for example, 3 mg / mL.

[0098] The buffer contained in the aqueous pharmaceutical composition is not particularly limited as long as it is pharma- ceutical acceptable, but a phosphate buffer is preferred. When a phosphate buffer is used as the buffer, the concentration of the phosphate buffer contained in the aqueous pharmaceutical composition is preferably 1 to 30 mM, more preferably 2 to 20 mM, even more preferably 5 to 15 mM, for example, about 10 mM. The pH of the aqueous pharmaceutical composition adjusted by the buffer is preferably 5.0 to 8.0, more preferably 6.0 to 7.8, even more preferably 6.5 to 7.6, even more preferably 7.0 to 7.4, for example, 7.2. The osmotic pressure ratio of the aqueous pharmaceutical composition to physiological saline is adjusted to, for example, 1.0 to 1.3.

[0099] A preferred composition of the aqueous pharmaceutical composition of the present invention is one in which the concentration of the protein combining serum albumin and growth hormone (particularly 22KhGH-mHSA) is 10-100 mg / mL, the concentration of the preservative is 0.5-12 mg / mL, the concentration of the sucrose is 10-150 mg / mL, the concentration of the nonionic surfactant is 0.15-10 mg / mL, the concentration of the preservative is 0.5-12 mg / mL, the concentration of the buffer is 1-30 mM, and the pH is 5.0-8.0.

[0100] Further preferred compositions of the aqueous pharmaceutical composition of the present invention include a concentration of serum albumin bound to growth hormone protein (particularly 22KhGH-mHSA) of 10-100 mg / mL, a concentration of sucrose of 75 mg / mL, a concentration of polyoxyethylene (160) polyoxypropylene (30) glycol of 3 mg / mL, a concentration of phenol of 6 mg / mL, a concentration of phosphate buffer of 10 mM, and a pH of 7.0-7.4. The concentrations of each component can be changed to any of the preferred concentrations above.

[0101] Further preferred compositions of the aqueous pharmaceutical composition of the present invention include a concentration of serum albumin bound to growth hormone protein (particularly 22KhGH-mHSA) of 15-70 mg / mL, a concentration of sucrose of 75 mg / mL, a concentration of polyoxyethylene (160) polyoxypropylene (30) glycol of 3 mg / mL, a concentration of phenol of 6 mg / mL, a concentration of phosphate buffer of 10 mM, and a pH of 7.0-7.4. The concentrations of each component can be changed to any of the preferred concentrations above.

[0102] Medicines containing the HSA-hGH fusion protein of the present invention (particularly 22K hGH-mHSA) as an active ingredient can be administered intravenously, intramuscularly, intraperitoneally, subcutaneously, or intracerebroventricularly as injections. These injections can be supplied as lyophilized preparations or aqueous liquid preparations (aqueous pharmaceutical compositions). In the case of aqueous liquid preparations, they may be filled in vials, or they can be supplied as prefilled preparations in syringes. In the case of lyophilized preparations, they are dissolved in an aqueous medium and reconstituted before use. EXAMPLES

[0103] The present invention will be described in more detail below with reference to examples, but it is not intended that the present invention be limited to the examples.

[0104] [Example 1] Construction of a vector for expressing 22K hGH-HSA A protein having the amino acid sequence shown in SEQ ID NO: 15, which is a combination of the C-terminus of 22KhGH and the N-terminus of wild-type HSA (SEQ ID NO: 1), was designated as 22KhGH-HSA. In the amino acid sequence shown in SEQ ID NO: 15, the 1st to 191st amino acid residues correspond to the amino acid sequence of 22KhGH, and the 192nd to 776th amino acid residues correspond to the amino acid sequence of HSA. A DNA having the base sequence shown in SEQ ID NO: 16, which includes a gene encoding 22KhGH-HSA (22KhGH-HSA gene), was chemically synthesized. In this sequence, bases 11 to 88 code for the leader peptide of hGH, bases 89 to 661 code for mature hGH, and bases 662 to 2416 code for mature HSA. This DNA was digested with restriction enzymes (MluI and NotI) and inserted between the MluI and NotI sites of pE-mIRES-GS-puro to construct pE-mIRES-GS-puro (22KhGH-HSA), a vector for expressing 22KhGH-HSA. Note that the method for constructing pE-mIRES-GS-puro is well known and is described in International Patent Publication WO2012 / 063799 and the like.

[0105] [Example 2] Construction of 22K hGH-mHSA expression vector The protein having the amino acid sequence shown in SEQ ID NO: 11, which is the C-terminus of 22KhGH (SEQ ID NO: 9) bound to the N-terminus of HSA (A320T) (SEQ ID NO: 3), was named 22KhGH-mHSA. Using pE-mIRES-GS-puro (22KhGH-HSA) prepared in Example 1 as a template, a DNA fragment containing a gene encoding 22KhGH-mHSA was amplified by PCR using primers YA082 (SEQ ID NO: 13) and YA083 (SEQ ID NO: 14). This DNA fragment was self-annealed to construct pE-mIRES-GS-puro (22KhGH-mHSA), which is a vector for expressing 22KhGH-mHSA.

[0106] [Example 3] Preparation of 22K hGH-mHSA expressing cell line Cells for expressing 22KhGH-mHSA were prepared as follows. The 22KhGH-mHSA expression vector pE-mIRES-GS-puro(22KhGH-mHSA) prepared in Example 2 was introduced into CHO-K1 cells, which are cells derived from Chinese hamster ovaries, using a Gene Pulser Xcell electroporation system (Bio Rad). The cells into which the expression vector was introduced were incubated in CD OptiCHO containing 16 μM thymidine, 100 μM hypoxanthine, 10 mg / L insulin, L-methionine sulfoximine (SIGMA) and puromycin (SIGMA). TM Selection culture was performed using a medium (Thermo Fisher Scientific). During the selection culture, the concentrations of L-methionine sulfoximine and puromycin were gradually increased to a final concentration of 300 μM for L-methionine sulfoximine and 10 μg / mL for puromycin to selectively grow cells exhibiting higher drug resistance. Next, the cells selected by the selection culture were seeded on a 96-well plate by limiting dilution so that one or less cell was seeded per well, and the cells were cloned by culturing for about 10 days until single-cell-derived colonies were formed. The cloned cells were further cultured and expanded, and then transferred to CD OptiCHO medium containing 16 μM thymidine, 100 μM hypoxanthine, 300 μM L-methionine sulfoximine, and 10% (v / v) DMSO. TM The cells were suspended in culture medium, dispensed into cryotubes, and stored in liquid nitrogen. These cells were designated as the 22K hGH-mHSA expressing cell line.

[0107] [Example 4] Preculture of 22K hGH-mHSA expressing cells The 22K hGH-mHSA expressing cell line prepared in Example 3 was thawed in a 37°C water bath, suspended in serum-free EX-CELL Advanced medium (preculture medium, SIGMA) containing 16 μM thymidine, 100 μM hypoxanthine, and 300 μM L-methionine sulfoximine, and centrifuged to precipitate the cells, and the supernatant was removed. The precipitated cells were diluted to 2 × 105 The cells were suspended in pre-culture medium at a density of 1.0 × 10 cells / mL or more and cultured at 37°C in the presence of 5% CO2 for 2 to 4 days. 11 This culture was repeated, expanding the culture scale until the cells proliferated to individual cells.

[0108] [Example 5] Production culture of 22K hGH-mHSA expressing cells The cells were grown in preculture at a cell concentration of 4 × 10 5 The cells were suspended at a density of 100 cells / mL in EX-CELL Advanced medium (production culture medium, SIGMA), a serum-free medium containing 16 μM thymidine and 100 μM hypoxanthine, in a volume of 200 L. This suspension was cultured for 10 days in a single-use culture tank of an Xcellerex200L culture system (XDR200) ​​at 37°C, with a dissolved oxygen content of 40% and a pH of 6.9, while stirring with an impeller at a speed of 100 rpm.

[0109] [Example 6] Purification of 22K hGH-mHSA (Refining process 1: Harvesting process / Concentration process 1) After the production culture was completed, the culture medium was filtered through a Millistak+® HC pod filter grade D0HC (1.1 ml 2 × 2, Merck) and then Millistak+HC pod filter grade X0HC (1.1 m 2 The cells were removed by filtration using a 1× filter (Merck) and then further filtered using an Opticap SHC XL3 (pore size: 0.5 / 0.2 μm, Merck) to obtain the culture supernatant. The culture supernatant was washed with pure water and then filtered using an ultrafiltration membrane device (Pellicon3 cassette, Ultracell PLCTK membrane installed, 1.14 m) with a molecular weight cutoff of 30 kDa that had been equilibrated with PBS. 2The concentrated culture solution was then concentrated using an ultrafiltration membrane device (Merck). The concentrated solution was recovered from the ultrafiltration membrane device. The inside of the device was then washed with PBS, and the weight of this washing solution was adjusted to approximately 15 kg with the concentrated solution previously recovered, to prepare the concentrated culture solution. The concentrated culture solution was then filtered using a hydrophilic filter (Opticap SHC XL600, Merck) with a maximum pore size of 0.5 μm and a minimum pore size of 0.2 μm. After filtration, the pH and electrical conductivity of the concentrated culture solution were confirmed to be 7.0±0.3 and 1.2±0.4 S / m, respectively.

[0110] (Purification step 2: First chromatography step (affinity column chromatography step)) A QS column (column volume: 4.2-5.2 L, bed height: 15.0±1.5 cm, Merck) packed with Capture select Human Growth Hormone Affinity Matrix (Thermo Fisher Scientific) was washed with 50 mM glycine hydrochloride buffer (pH 3.0) of 1 column volume, and then with 0.01 M sodium hydroxide aqueous solution of 1 column volume, and then equilibrated with 20 mM Tris-HCl buffer (pH 7.0) of 4 column volumes. Next, 1 / 4 of the concentrated culture fluid obtained in purification step 1 was loaded onto the column to adsorb 22K hGH-mHSA onto the column. Next, the column was washed with 20 mM Tris-HCl buffer (pH 7.0) containing 200 mM arginine and 0.05% (w / v) polysorbate 80 of 5 column volumes, and then with 20 mM Tris-HCl buffer (pH 7.0) of 5 column volumes. Next, 50 mM glycine hydrochloride buffer (pH 3.0) was supplied to the column in a volume 5 times the column volume to elute 22K hGH-mHSA. The eluate was collected in a container that had previously contained 250 mM MES buffer (pH 7.0) in a volume 1 / 5 of the eluate volume, and immediately neutralized to a pH of 6.7 ± 0.3. Purification step 2 was performed at a cold temperature of 4 to 8°C, and the linear flow rate of the solution supplied to the column throughout purification step 2 was 200 cm / hour. The upper limit of 22K hGH-mHSA that could be loaded per 1 L of affinity column carrier was 7 g.

[0111] (Purification process 3: Virus inactivation process) The eluate obtained in purification step 2 was warmed to 25°C, and a 6.0% (v / v) aqueous solution of tri(n-butyl)phosphate containing 20.0% (w / v) polysorbate 80 (1 / 19 of the volume of the eluate) was added to the eluate, followed by stirring at 25°C for 3 hours.

[0112] (Purification step 4: Second chromatography step (hydroxyapatite column chromatography step)) The fraction that had been subjected to the virus inactivation treatment in purification step 3 was cooled to 8°C, and appropriate amounts of 1 M Tris-HCl buffer (pH 8.8) and 20 mM MES buffer (pH 7.0) containing 4 M NaCl were added to adjust the pH and conductivity to 7.0±0.1 and 0.6±0.1 S / m, respectively, and filtered using a hydrophilic filter with a pore size of 0.2 μm (Merck). The following chromatography was then performed under refrigeration (linear flow rate: 200 cm / h).

[0113] A QS column (column volume: 8.8-10.8 L, bed height: 20.0±2.0 cm, Merck) packed with hydroxyapatite support CHT Type II, 40 μm (Bio-Rad Laboratories) was washed with 200 mM phosphate buffer (pH 7.0), then 1 M NaOH aqueous solution, and then 200 mM phosphate buffer (pH 7.0), and then equilibrated with 4 volumes of 20 mM MES buffer (pH 7.0) containing 50 mM NaCl and 1 mM sodium dihydrogen phosphate. The filtrate was then loaded onto the column to adsorb 22KhGH-mHSA onto the column. The column was then washed with 3 volumes of 20 mM MES buffer (pH 7.0) containing 50 mM NaCl and 1 mM sodium dihydrogen phosphate. Next, 20 mM MES buffer (pH 7.0) containing 50 mM NaCl and 30 mM sodium dihydrogen phosphate was applied to the column to elute 22K hGH-mHSA. Purification step 4 was performed at a cold temperature of 4 to 8°C, and the linear flow rate of the solution applied to the column throughout purification step 4 was 200 cm / h. The upper limit of 22K hGH-mHSA that could be loaded per 1 L of hydroxyapatite carrier was 13 g.

[0114] (Purification step 5: Third chromatography step (multimodal weak cation exchange column chromatography step)) The eluate obtained in purification step 4 was mixed with the same volume of 20 mM MES buffer (pH 5.7) containing 50 mM NaCl, and then diluted hydrochloric acid was added to adjust the pH and conductivity to 5.7±0.1 and 0.7±0.1 S / m, respectively. The mixture was then filtered using a hydrophilic filter (Merck) with a pore size of 0.5 / 0.2 μm.

[0115] A prepacked column RTP Capto MMC 10 L (column volume: 8.8-10.8 L, bed height: 20.0±2.0 cm, Merck) was washed with 1 M NaOH aqueous solution, then with 50 mM phosphate buffer (pH 7.0) containing 1 M NaCl, and then equilibrated with 4 volumes of 50 mM MES buffer (pH 5.7) containing 100 mM NaCl. The above filtrate was then loaded onto the column to adsorb 22K hGH-mHSA onto the column. The column was then washed with 5 volumes of 50 mM MES buffer (pH 5.7) containing 100 mM NaCl. 22K hGH-mHSA was then eluted by supplying 50 mM MES buffer (pH 5.7) containing 550 mM NaCl to the column. Purification step 5 was performed at a cold temperature of 4-8°C, and the linear flow rate of the solution supplied to the column throughout purification step 5 was 200 cm / h. The upper limit of the amount of 22K hGH-mHSA that can be loaded per 1 L of the multimodal weak cation exchange carrier was set at 11.5 g.

[0116] (Purification step 6: Concentration step 2) Ultrafiltration membrane with molecular weight cutoff of 30 kDa (Pellicon3 Cassette Ultracel PLCTK Membrane 1.14 m 2 After thorough washing with pure water, the ultrafiltration membrane was equilibrated with 10 mM phosphate buffer (pH 7.2) containing 75 mg / mL sucrose. The eluate obtained in purification step 5 was concentrated using this ultrafiltration membrane. To the concentrated solution, 10 mM phosphate buffer (pH 7.2) containing 75 mg / mL sucrose was added to adjust the absorbance (280 nm) to 23 ± 3. This concentration step was carried out at room temperature.

[0117] (Purification step 7: Fourth chromatography step (size exclusion column chromatography step)) The concentrate obtained in the purification step 6 was filtered using a hydrophilic filter with a pore size of 0.5 / 0.2 μm (Merck). TM A QS column (column volume: 25.4-31.1 L, bed height: 40.0±4.0 cm, Merck) packed with BioSEC resin (Merck) was washed with 0.5M NaOH aqueous solution and then equilibrated with 10 mM phosphate buffer (pH 7.2) containing 75 mg / mL sucrose. The above filtrate was then loaded onto the column, followed by the supply of 10 mM phosphate buffer (pH 7.2) containing 75 mg / mL sucrose. At this time, an absorption spectrophotometer was placed in the flow path of the eluate from the size exclusion column to continuously measure the absorbance of the eluate, and the absorbance at 280 nm was monitored. The fractions that showed an absorption peak at 280 nm were collected as fractions containing 22K hGH-mHSA, and these were used as the purified 22K hGH-mHSA product. Purification step 7 was performed at room temperature, and the linear flow rate of the solution supplied to the column throughout purification step 7 was 30 cm / h or less. The volume of the filtrate containing 22K hGH-mHSA loaded onto the multimodal weak cation exchange carrier was set to 8% or less of the carrier volume.

[0118] (Purification step 8: Concentration step 3) A hollow fiber membrane (ReadyToProcess Hollow Fiber Cartridge, molecular weight cutoff 30 kDa, GE Healthcare) was equilibrated with 10 mM phosphate buffer (pH 7.2) containing 75 mg / mL sucrose. Using this hollow fiber membrane, the 22K hGH-mHSA purified product obtained in purification step 7 was concentrated, and the concentration of 22K hGH-mHSA was adjusted to 85 mg / mL. The resulting concentrated solution was mixed with 10 mM phosphate buffer (pH 7.2) containing 90 mg / mL poloxamer 188 and 75 mg / mL sucrose in a volume of 1 / 29 of the liquid volume, and filtered using a hydrophilic filter with a pore size of 0.5 / 0.2 μm (Merck). This concentration step was carried out at room temperature.

[0119] (Purification process 9: Virus removal process) A 10 mM phosphate buffer (pH 7.2) containing 3 mg / mL poloxamer 188 and 75 mg / mL sucrose was prepared. This buffer was used to prepare a virus removal membrane (Planova 20N, membrane area: 0.12 m 2 A virus removal membrane (material: regenerated cellulose, Asahi Kasei Medical Co., Ltd.) was equilibrated. The filtrate obtained in the purification step 8 was passed through this virus removal membrane at a pressure of 98 kPa or less. This virus removal step was carried out at room temperature.

[0120] (Purification step 10: Drug substance production step) The filtrate obtained in purification step 9 was filtered at room temperature through a hydrophilic filter (Merck) with a pore size of 0.2 μm to obtain 22K hGH-mHSA bulk drug.

[0121] [Example 7] Study on the stability of an aqueous pharmaceutical composition containing 22KhGH-mHSA 1 Using the 22KhGH-mHSA drug substance obtained in Example 6, six types of aqueous pharmaceutical compositions (formulations 1-1 to 1-6) containing 15 mg / mL 22KhGH-mHSA and 20 mM phosphate buffer and having different pH values ​​and the compositions shown in Table 1 were prepared.

[0122] [Table 1]

[0123] The six types of aqueous pharmaceutical compositions were filled in glass vials in an amount of 1.5 mL each, and stored in a dark place at 5°C for one week or at 40°C for one week. After storage, the ratio of the monomer of 22KhGH-mHSA, its polymer, and its decomposition product, low molecular weight substance, contained in each solution was measured by SE-HPLC analysis shown in Example 13. The results are shown in Table 2. Here, the condition for a stable aqueous pharmaceutical composition was previously determined to be that the ratio of the polymer and low molecular weight substance contained in the solution after storage in a dark place at 5°C for one week and at 40°C for one week is approximately 2% or less. The results in Table 2 show that, under these measurement conditions, in order to obtain a stable aqueous pharmaceutical composition of 22KhGH-mHSA, it is preferable to set the pH to 6.0 or more, and particularly preferably to set the pH to 6.5 to 7.5.

[0124] [Table 2]

[0125] [Example 8] Study on the stability of an aqueous pharmaceutical composition containing 22KhGH-mHSA 2 Using the 22KhGH-mHSA drug substance obtained in Example 6, three types of aqueous pharmaceutical compositions (formulations 2-1 to 2-3) containing 15 mg / mL 22KhGH-mHSA and 20 mM phosphate buffer, with different concentrations of sucrose and sodium chloride, as shown in Table 3, were prepared. The pH of each solution was adjusted to 7.0, and the osmotic pressure ratio was adjusted to about 1.0. Using a protein physical property analyzer (Optim1000, AVACTA), 9 μL of the measurement sample was placed in a cuvette (UNi, UNCHAINED LABS), and the cuvette was heated from 20.0°C to 96.0°C in 1°C increments, and the static light scattering intensity at a wavelength of 473 nm was measured for each temperature.

[0126] [Table 3]

[0127] A graph of the measurement results of static light scattering intensity is shown in Figure 1. In Figure 1, the vertical axis indicates the static light scattering intensity, and there is a positive correlation between this static light scattering intensity and the concentration of fine particles generated by the aggregation of proteins contained in the solution. The temperature at which aggregation begins to occur is almost the same for Formulations 2-1 to 2-3, but the amount of fine particles generated by increasing the temperature tends to increase with the increase in the concentration of sodium chloride. Therefore, in order to suppress the aggregation of 22KhGH-mHSA contained in the solution, it can be said that sucrose is more preferable than sodium chloride as an excipient to be added to the aqueous pharmaceutical composition.

[0128] [Example 9] Study on the stability of aqueous pharmaceutical composition containing 22K hGH-mHSA 3 Using the 22KhGH-mHSA bulk drug obtained in Example 6, six types of aqueous pharmaceutical compositions (formulations 3-1 to 3-6) containing 35 mg / mL 22KhGH-mHSA, 20 mM phosphate buffer, and 70 mg / mL sucrose, and differing in the concentration of nonionic surfactant (poloxamer 188), as shown in Table 4, were prepared. The pH of each solution was adjusted to 7.2, and the osmotic pressure ratio was adjusted to approximately 1.0.

[0129] [Table 4]

[0130] The six types of aqueous pharmaceutical compositions were filled in glass vials in an amount of 1 mL each, and shaken at room temperature for 24 hours at 240 reciprocations / min. The ratio of polymer to the total 22KhGH-mHSA contained in each solution before and after shaking was measured by SE-HPLC analysis as shown in Example 13, and the polymer increase (%) was calculated by subtracting the polymer content (%) before shaking from the polymer content (%) after shaking. The results are shown in Table 5. Under these conditions, the formation of polymer can be suppressed by making the concentration of poloxamer 188 1.0 mg / mL or more, and the formation of polymer can be almost completely suppressed by making the concentration 1.5 mg / mL or more. In addition, in the case of formulation 3-1 not containing poloxamer 188, a large amount of polymer was formed, so no measurement value could be obtained.

[0131] [Table 5]

[0132] Next, five types of aqueous pharmaceutical compositions (formulations 4-1 to 4-5) were prepared, each having a 22K hGH-mHSA concentration of 130 mg / mL, containing 20 mM phosphate buffer and 70 mg / mL sucrose, and differing in the concentration of nonionic surfactant (poloxamer 188), as shown in Table 6. The pH of each solution was adjusted to 7.2, and the osmotic pressure ratio was adjusted to approximately 1.0.

[0133] [Table 6]

[0134] The above five types of aqueous pharmaceutical compositions were filled in glass vials in an amount of 0.8 mL each, and shaken at room temperature at 240 reciprocations / min for 24 hours. After shaking, the ratio of polymer and low molecular weight substances to the total amount of 22KhGH-mHSA contained in each solution was measured by SE-HPLC analysis as shown in Example 13. The results are shown in Table 7. In all of Formulations 4-1 to 4-5, the values ​​of the polymer content (%) and low molecular weight substance content (%) were almost unchanged from the values ​​before shaking (data before shaking is not shown), and the values ​​of the polymer content (%) and low molecular weight substance content (%) were equivalent in all formulations.

[0135] [Table 7]

[0136] [Example 10] Study on the stability of aqueous pharmaceutical composition containing 22K hGH-mHSA 4 Using the 22KhGH-mHSA bulk drug obtained in Example 6, three types of aqueous pharmaceutical compositions (formulations 5-1 to 5-3) with different pH values ​​and compositions shown in Table 8 were prepared, containing 35 mg / mL 22KhGH-mHSA, 20 mM phosphate buffer, 70 mg / mL sucrose, 1.0 mg / mL nonionic surfactant (poloxamer 188) and 3.3 mg / mL phenol as a preservative.

[0137] [Table 8]

[0138] The above three types of aqueous pharmaceutical compositions were filled in glass vials in an amount of 1 mL each and stored in a dark place at 5° C. or 25° C. for two months. The ones stored at 5° C. were subjected to the SE-HPLC analysis described in Example 13 and the particle count analysis described in Example 15 after two weeks, one month, and two months, respectively, and the ones stored at 25° C. were subjected to the SE-HPLC analysis described in Example 13 and the particle count analysis described in Example 15 after one month and two months. The results are shown in Table 9.

[0139] Regarding the polymer content measured by SE-HPLC, in the case of formulation 5-3 adjusted to pH 7.2, there was almost no change when left at rest for one month at 5°C or for two months at 25°C. On the other hand, in the case of formulation 5-1 adjusted to pH 6.2, there was an increase in the polymer content over time when left at rest for one month at 5°C or for two months at 25°C. In the case of formulation 5-2 adjusted to pH 6.7, there was no change in the polymer content when left at rest for one month at 5°C, but there was an increase in the polymer content over time when left at rest for two months at 25°C. Regarding the low molecular weight content measured by SE-HPLC, there was almost no change in any of formulations 5-1 to 5-3 when left at rest for one month at 5°C. On the other hand, an increase in the low molecular weight content was observed in all formulations when left at rest for two months at 25°C, but the increase was slight. With regard to particle count analysis, in formulation 5-3 adjusted to pH 7.2, the number of particles 10 μm or larger and 25 μm or larger was significantly reduced compared to formulations 5-1 and 5-2.

[0140] [Table 9]

[0141] [Example 11] Formulation design of aqueous pharmaceutical composition From the results shown in Examples 7 to 10 above, as a suitable example of the formulation of the aqueous pharmaceutical composition containing 22KhGH-mHSA, a composition shown in Table 10 (Formulation 6) containing 50 mg / mL 22KhGH-mHSA, 10 mM phosphate buffer, 75 mg / mL sucrose, 3 mg / mL poloxamer 188, and 6 mg / mL phenol, adjusted to pH 7.2 and osmotic pressure ratio of about 1.0, can be designed. This aqueous pharmaceutical composition can be filled and sealed in a glass or plastic vial, ampoule, or syringe with a liquid volume of 0.5 to 10 mL. The composition can also be supplied as a prefilled formulation by filling it in a syringe in advance. The storage temperature is preferably 2 to 10°C, for example 4°C, and storage in a refrigerator capable of recording temperature is envisaged.

[0142] [Table 10]

[0143] [Example 12] Study on the stability of aqueous pharmaceutical composition containing 22K hGH-mHSA 5 An aqueous pharmaceutical composition of Formulation 6 having the composition shown in Table 10 was prepared, 1.7 mL was filled into a borosilicate glass cartridge, and the composition was stored in the dark at 5°C for 12 months. After 3 months, 6 months, and 12 months, the properties test described in Example 14, the insoluble foreign matter test and pH measurement described in Example 16, the SE-HPLC analysis described in Example 13, the particle number analysis described in Example 15, and the 22KhGH-mHSA quantification described in Example 17 were performed. The results are shown in Table 11. There was no significant change in any of the test values, and it can be seen that Formulation 6 is stable as an aqueous pharmaceutical composition containing 22KhGH-mHSA for at least 12 months. In Table 11, the quantification method (relative to theoretical value (%)) indicates the actual quantification value (%) when the amount of 22KhGH-mHSA at the time of preparation of Formulation 6 is taken as 100%.

[0144] [Table 11]

[0145] [Example 13] SE-HPLC analysis (measurement of polymer, monomer and low molecular weight content of 22KhGH-mHSA using SE-HPLC) Sodium dihydrogen phosphate dihydrate and sodium chloride were dissolved in water to prepare a phosphate buffer solution containing 0.1 M phosphoric acid and 0.2 M sodium chloride. In addition, a solution with the same composition as each aqueous pharmaceutical composition to be tested but without 22KhGH-mHSA or phenol was prepared and used as the sample diluent.

[0146] The aqueous pharmaceutical composition to be tested was adjusted to a protein concentration of 2.0 mg / mL using a sample diluent to prepare a sample solution.

[0147] HPLC system (LC-20A, Shimadzu Corporation) and column (TSKgel G3000SW XLMeasurements were performed using a chromatograph (Tosoh Corporation) under the conditions shown in Table 12 below. However, the flow rate was not necessarily limited to the conditions shown in Table 12, and was adjusted appropriately so that the retention time of the main peak was around 12 minutes. A typical chromatogram is shown in Figure 2. On the chromatogram obtained by measuring the sample solution, the main peak detected at a retention time of around 12 minutes was taken as monomer, the peak detected before the main peak as polymer, and the peak detected after the main peak as low molecular weight substance, and the main peak content (%), polymer content (%), and low molecular weight content (%) were calculated from the area of ​​each peak. Note that the peak detected around 23.5 minutes was derived from phenol, and was therefore excluded from the analysis. In addition, peaks that were the same as those detected on the chromatogram obtained by measuring the diluted sample solution were also excluded from the analysis of the sample solution.

[0148] [Table 12]

[0149] [Example 14] Property test The following liquids were used as color comparison liquids. (1) Color Reference Solutions B Set (brown, Sigma-Aldrich) (2) Color Reference Solutions BY set (brownish yellow, Sigma-Aldrich) (3) Color Reference Solutions Y Set (yellow, Sigma-Aldrich)

[0150] The containers (vials, etc.) containing the aqueous pharmaceutical composition to be tested were observed from the side using black and white backgrounds to confirm the color tone and clarity. A color comparison liquid may be used to judge the color tone.

[0151] [Example 15] Measurement of particle count Measurement conditions: Measurements were performed using a flow site particle image analyzer (FlowCam VS-1, FLUID IMAGING TECHNOLOGIES) under the conditions shown in Table 13 below. A flow cell (FC80FV-5, FLUID IMAGING TECHNOLOGIES) was used to count the number of microparticles (particles / mL) contained in the aqueous pharmaceutical composition being tested. The number of microparticles was measured by counting the number of particles with diameters of 10 μm or more and 25 μm or more.

[0152] [Table 13]

[0153] [Example 16] Methods for testing for insoluble foreign matter, measuring pH, and measuring osmotic pressure ratio Insoluble foreign matter testing, pH measurement, and osmotic pressure ratio measurement were performed according to the general methods specified in the Japanese Pharmacopoeia. Insoluble foreign matter testing is a method for visually confirming the presence or absence of easily detectable insoluble foreign matter.

[0154] [Example 17] Quantitation of 22K hGH-mHSA (Bradford method) A 22K hGH-mHSA solution of known concentration was diluted with water to prepare solutions containing 1.0, 0.8, 0.6, 0.4, and 0.2 mg / mL of 22K hGH-mHSA, which were designated as standard solutions 1 to 5. The aqueous pharmaceutical composition to be tested was diluted with water so that the protein concentration was in the range of 0.4 to 0.8 mg / mL to prepare the sample solutions.

[0155] Reaction with Coomassie test solution: Pierce TM5 mL of Pierce Coomasie Assay Reagent included in the Coomassie (Bradford) Protein Assay Kit (ThermoFisher SCIENTIFIC) was taken into 15 mL centrifuge tubes, the number of tubes required for the measurement. Next, 100 μL of water (for blank), standard solutions 1 to 5, and sample solution were added to each 15 mL centrifuge tube containing the Pierce Coomasie Assay Reagent, and the tubes were mixed by inversion and left to stand at room temperature for 10 minutes to react. Immediately after the reaction, 2 mL or more of the sample was placed in a measurement cell (cuvette, light path length 10 mm, light path width 10 mm, Sarstedt) using a spectrophotometer (UV-2600, Shimadzu Corporation), and absorbance was measured at a wavelength of 595 nm. The absorbance of standard solutions 1 to 5 was plotted on the Y axis and the theoretical protein concentration on the X axis, and a regression line (calibration curve) was created to calculate the protein concentration from the absorbance of the sample solution. [Industrial Applicability]

[0156] According to the present invention, a medicine containing, as an active ingredient, a protein in which serum albumin and growth hormone are linked, can be distributed on the market in the form of an aqueous pharmaceutical composition. [Sequence List Free Text]

[0157] SEQ ID NO: 1: Amino acid sequence of wild-type human serum albumin SEQ ID NO:2: Amino acid sequence of human serum albumin Redhill SEQ ID NO: 3: Amino acid sequence of human serum albumin mutant (A320T) SEQ ID NO: 4: Example 1 of the amino acid sequence of the linker SEQ ID NO: 5: Example 2 of the amino acid sequence of the linker SEQ ID NO: 6: Example 3 of the amino acid sequence of the linker SEQ ID NO: 7: Partial base sequence of the internal ribosome binding site derived from wild-type murine encephalomyocarditis virus SEQ ID NO: 8: Partial base sequence of the internal ribosome binding site from a mutant murine encephalomyocarditis virus, synthetic SEQ ID NO:9: Amino acid sequence of 22K human growth hormone SEQ ID NO: 10: Amino acid sequence of 20K human growth hormone SEQ ID NO: 11: Amino acid sequence of 22KhGH-mHSA SEQ ID NO: 12: Amino acid sequence of 20KhGH-mHSA SEQ ID NO: 13: Primer YA082, synthetic sequence SEQ ID NO: 14: Primer YA083, synthetic sequence SEQ ID NO: 15: Amino acid sequence of 22KhGH-HSA SEQ ID NO: 16: Nucleotide sequence containing the 22KhGH-HSA gene, synthetic sequence

Claims

1. An aqueous pharmaceutical composition comprising a fusion protein of human serum albumin and human growth hormone as an active ingredient, the concentration of the fusion protein is 10-100 mg / mL, the concentration of sucrose is 10-150 mg / mL, the concentration of polyoxyethylene (160) polyoxypropylene (30) glycol is 0.15-10 mg / mL, the concentration of phenol is 3-9 mg / mL, the concentration of phosphate buffer is 1-30 mM, and the pH is 5.0-8.0; The amino acid sequence of the fusion protein has 90% or more identity with the amino acid sequence shown in SEQ ID NO:

11.

2. 2. The aqueous pharmaceutical composition according to claim 1, wherein the concentration of the fusion protein is 15 to 70 mg / mL.

3. 3. The aqueous pharmaceutical composition according to claim 1 or 2, wherein the concentration of the sucrose is 50 to 100 mg / mL.

4. 4. The aqueous pharmaceutical composition according to claim 1, wherein the concentration of the polyoxyethylene (160) polyoxypropylene (30) glycol is 1.5 to 4.5 mg / mL.

5. 5. The liquid pharmaceutical composition according to claim 1, wherein the concentration of the phosphate buffer is 2 to 20 mM.

6. 6. The aqueous pharmaceutical composition according to claim 1, wherein the pH is 6.0 to 7.

8.

7. 6. The liquid pharmaceutical composition according to claim 1, wherein the pH is 6.5 to 7.

6.

8. 2. The aqueous pharmaceutical composition according to claim 1, wherein the fusion protein has a concentration of 10 to 100 mg / mL, the sucrose has a concentration of 75 mg / mL, the polyoxyethylene (160) polyoxypropylene (30) glycol has a concentration of 3 mg / mL, the phenol has a concentration of 6 mg / mL, the phosphate buffer has a concentration of 10 mM, and the pH is 7.0 to 7.

4.

9. 2. The aqueous pharmaceutical composition according to claim 1, wherein the concentration of the fusion protein is 15 to 70 mg / mL, the concentration of the sucrose is 75 mg / mL, the concentration of the polyoxyethylene (160) polyoxypropylene (30) glycol is 3 mg / mL, the concentration of the phenol is 6 mg / mL, the concentration of the phosphate buffer is 10 mM, and the pH is 7.0 to 7.

4.

10. 2. The aqueous pharmaceutical composition according to claim 1, wherein the concentration of the fusion protein is 50 mg / mL, the concentration of the sucrose is 75 mg / mL, the concentration of the polyoxyethylene (160) polyoxypropylene (30) glycol is 3 mg / mL, the concentration of the phenol is 6 mg / mL, the concentration of the phosphate buffer is 10 mM, and the pH is 7.0 to 7.

4.

11. 11. The liquid pharmaceutical composition according to claim 1, wherein the amino acid sequence of the fusion protein has 95% or more identity with the amino acid sequence shown in SEQ ID NO:

11.

12. 11. The liquid pharmaceutical composition according to claim 1, wherein the amino acid sequence of the fusion protein has the amino acid sequence shown in SEQ ID NO:11.

Images